Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
Listen to Naval G. Daver, MD, discuss his thoughts on the most promising investigational agents and treatment strategies currently in clinical trials for the treatment of patients with acute myeloid leukemia (AML).
Decera Clinical Education Oncology Podcast
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:
- FLT3 inhibitors crenolanib and quizartinib
- Anti-CD47 antibody magrolimab
- IMGN632, a CD123 antibody–drug conjugate
- Anti-CD70 antibody cusatuzumab
- APR-246, targeting the TP53 mutation
Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.
Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.